What should Mexican Policymakers know about biosecurity and GBRCs?

There is often a gap between biosecurity research/theory and actual policy implementation, particularly in the Global South. While we discuss Global Catastrophic Biological Risks and dual-use research governance in abstract terms, translating these concepts into actionable frameworks for legislators and ministries in emerging economies requires a specific kind of translation.

I am writing to request community input on curriculum prioritization.

The Context: BioXPol Mexico In May 2026, with the support of the United Nations University Biotechnology Programme for Latin America and the Caribbean (UNU-BIOLAC), I will be launching a new edition of BioXPol in Mexico City.

This is a training program designed specifically for decision-makers across Secretariats of State (Foreign Affairs, Health, Science & Technology), Legislative Chambers (Deputies and Senators involved in Science Commissions) and International Organization delegates based in the region.

Track Record: This is not a pilot experiment. We have successfully implemented versions of this methodology in Guatemala and Panama, training over 200 individuals. However, the Mexico edition represents a significant scale-up due to the country's geopolitical relevance and its growing bio-economy ecosystem.

The Challenge: Curating the Curriculum Mexico has robust frameworks for traditional GMO biosafety, but gaps remain regarding emerging biotechnologies, dual-use research of concern (DURC), and macro-biosecurity governance.

My goal is to move the needle from "basic safety" to "anticipatory governance."

I would value the Forum’s perspective on:

1. Prioritization: If you had 2 hours with a high-ranking Mexican legislator, what is the single most critical biosecurity bottleneck you would ask them to address? (e.g., DNA synthesis screening, BWC compliance, pathogen surveillance infrastructure).
2. Framing: How can we best frame GCBRs to political actors in Latin America without sounding overly speculative or detached from their immediate development priorities?
3. Case Studies: Are there specific "success stories" or "cautionary tales" of biosecurity policy implementation in other emerging economies that you recommend we include?

I look forward to your insights, resources, or connections to others working on policy implementation in the region.

(Note: If you are coming to CDMX for EAGx, let me know! I’d be happy to discuss this)